浙江醫藥(600216.SH)擬由合夥企業增資子公司新碼生物
格隆匯 8 月 25日丨浙江醫藥(600216.SH)公佈,公司擬由紹興源智生物醫藥合夥企業(有限合夥)增資子公司浙江新碼生物醫藥有限公司(“新碼生物”),增資擴股數量63萬股,價格為37元/股,合計金額2331萬元。
紹興源智生物醫藥合夥企業(有限合夥)的部分合夥人在公司擔任董事、監事及高級管理人員,具體情況如下:呂春雷、李男行、朱金林、馬文鑫為公司董事,曹勇、陳春峯、何益民、戚偉紅為公司監事,俞煥明、張定豐、葉偉東、呂旭峯、王紅衞、張培紅為公司高級管理人員。根據《上海證券交易所股票上市規則》及《上海證券交易所上市公司關聯交易實施指引》的有關規定,此次交易構成關聯交易。此次關聯交易不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.